Preclinical-stage biopharmaceutical developer of disease‑modifying therapies for Alzheimer’s disease and related dementias, targeting tau homeostasis/seeding and microglia-driven neuroinflammation. Uses human genetics‑anchored discovery and translational biomarkers to identify the right patients and monitor therapeutic response.